Westfield Capital Management Co. LP Sells 393,820 Shares of Icon Plc $ICLR

Westfield Capital Management Co. LP lowered its position in shares of Icon Plc (NASDAQ:ICLR) by 99.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,534 shares of the medical research company’s stock after selling 393,820 shares during the quarter. Westfield Capital Management Co. LP’s holdings in Icon were worth $462,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the company. Harris Associates L P bought a new position in shares of Icon during the 2nd quarter worth about $238,256,000. Wellington Management Group LLP boosted its position in shares of Icon by 26.6% during the 3rd quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock worth $811,499,000 after purchasing an additional 975,268 shares in the last quarter. Norges Bank bought a new position in shares of Icon during the 4th quarter worth about $160,073,000. Franklin Resources Inc. boosted its position in shares of Icon by 35.4% during the 3rd quarter. Franklin Resources Inc. now owns 2,753,528 shares of the medical research company’s stock worth $481,692,000 after purchasing an additional 719,301 shares in the last quarter. Finally, Boston Partners boosted its position in shares of Icon by 1,207.3% during the 3rd quarter. Boston Partners now owns 739,135 shares of the medical research company’s stock worth $129,372,000 after purchasing an additional 682,597 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

Analyst Ratings Changes

ICLR has been the topic of a number of research analyst reports. BMO Capital Markets increased their price objective on shares of Icon from $130.00 to $160.00 and gave the stock an “outperform” rating in a research report on Friday, May 29th. DA Davidson set a $164.00 price objective on shares of Icon in a research report on Monday, June 1st. Leerink Partners set a $145.00 price objective on shares of Icon in a research report on Thursday, May 28th. Royal Bank Of Canada increased their price objective on shares of Icon from $123.00 to $126.00 and gave the stock a “sector perform” rating in a research report on Friday, May 29th. Finally, Piper Sandler cut shares of Icon to a “neutral” rating in a research report on Thursday, May 28th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $156.44.

Icon Price Performance

Shares of NASDAQ ICLR opened at $149.45 on Friday. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $211.00. The stock has a market cap of $12.07 billion, a price-to-earnings ratio of 24.26, a PEG ratio of 10.13 and a beta of 1.26. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.10 and a current ratio of 1.10. The firm’s 50-day simple moving average is $117.51 and its 200 day simple moving average is $140.85.

Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, May 27th. The medical research company reported $2.21 earnings per share for the quarter. Icon had a net margin of 5.98% and a return on equity of 9.50%. The business had revenue of $2.11 billion for the quarter. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. As a group, research analysts anticipate that Icon Plc will post 9.74 earnings per share for the current fiscal year.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.